Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
6.97
-0.13 (-1.83%)
At close: Oct 16, 2026, 4:00 PM EDT
6.87
-0.10 (-1.48%)
After-hours: Oct 16, 2026, 7:30 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
95.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Atara Biotherapeutics | 6.19M |
| Rani Therapeutics Holdings | 4.88M |
| Cibus | 4.35M |
| Kazia Therapeutics | 1.27M |
IMUX News
- 10 days ago - Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting - PRNewsWire
- 5 weeks ago - Immunic Transcript: R&D Day 2026 - Transcripts
- 5 weeks ago - Immunic Slides: FY 2026 - Filings
- 6 weeks ago - Immunic Slides: Corporate presentation - Filings
- 6 weeks ago - Immunic Slides: Investor presentation - Filings
- 6 weeks ago - Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PRNewsWire
- 6 weeks ago - Immunic price target raised to $29 from $19 at Roth Capital - TheFly
- 6 weeks ago - Immunic appoints Chitrang Dave as chief data, digital officer - TheFly